Zack Scott
Managing Partner
Get their honest, personalized take on your startup.
Sign in to pitch Zack →At a glance
- Full Name
- Zack Scott, MD
- Title
- General Partner and Co-Head of Healthcare
- Firm
- Norwest Venture Partners (formerly co-founder & Managing Partner, Revelation Partners)
- Firm Type
- Multi-stage venture capital & growth equity (healthcare practice)
- Investment Stage
- Early-stage venture through growth (not seed/angel as originally stubbed)
- Check Size
- Not publicly disclosed; Norwest deploys from a large multi-billion-dollar fund and writes venture-to-growth-sized checks (e.g., $4M into VenoStent's Series A)
- Target Company Profile
- Healthcare companies with proven or clearly de-risked clinical, regulatory, and commercial pathways — provider-focused businesses, novel medical devices, and data/real-world-evidence platforms
- Sector Focus
- Medical devices, diagnostics, therapeutics, life science, healthcare services, and healthtech/real-world data
- Geographic Focus
- North America
- Location
- San Francisco Bay Area, California
Background
Zack Scott, MD, is a General Partner and Co-Head of the healthcare investment team at Norwest Venture Partners, which he joined in September 2022. He is a physician-turned-investor whose focus spans medical devices, diagnostics, therapeutics, and healthtech, with a particular interest in provider-focused businesses that sell to hospital systems and physicians, and in pharmatech and real-world-evidence platforms.
Before Norwest, Scott co-founded Revelation Partners in 2013 and served as its Managing Partner for roughly nine years. Revelation is a San Francisco–based, healthcare-dedicated secondary investor that acquires late-stage private healthcare positions from existing shareholders and provides growth capital across medical devices, biopharma, healthcare IT, and services. Earlier in his career, he was an investor at Burrill & Company, where he led healthcare investments across medical devices, diagnostics, and biopharmaceuticals.
Scott's path into investing is clinical: he trained as a General Surgery resident at Oregon Health & Science University in Portland, Oregon. He earned his M.D. from the University of Texas Health Science Center at San Antonio (UT Health San Antonio), where he was elected to the Alpha Omega Alpha (AOA) medical honor society, and an M.B.A. with a certificate in Health Sector Management from Duke University's Fuqua School of Business, where he was a Fuqua Scholar.
He is an active board member. His current and past board seats include Apreo Health, Cytovale, Galvanize Therapeutics, Nectero Medical, SetPoint Medical, ShiraTronics, and VenoStent (board observer) at Norwest, plus earlier seats at Cianna Medical, Coherex Medical, Evidation Health, Omada Health, iRhythm Technologies, Providence Medical Technology, Respicardia, Spiration, Syapse, and Vertos Medical.
Investment Thesis & Focus
- Invests across medical devices, diagnostics, therapeutics, life science, and healthcare services/healthtech, concentrated in North America.
- Favors provider-focused businesses selling to hospital systems and physicians, and pharmatech / real-world-evidence data businesses.
- Looks for companies with proven commercial models or novel technologies with clear clinical and regulatory pathways — a discipline carried over from his secondary-investing years at Revelation.
- In his own words: *"I like to invest in companies and products that will have a meaningful impact for the healthcare system as a whole."*
- On his data-driven angle: *"Real-world data gives us a view of the patient journey that we haven't had before."*
- Brings a physician + operator lens (surgical training, MD/MBA) to diligence, especially on clinical validation and reimbursement.
Notable Investments
- VenoStent — bioabsorbable vascular wrap; Norwest invested $4M as part of a $20M Series A (2024); Scott joined as board observer.
- SetPoint Medical — bioelectronic therapy for chronic autoimmune diseases; board seat.
- Cytovale — sepsis diagnostics (IntelliSep); board seat.
- ShiraTronics — implantable neurostimulation system for chronic migraine; board seat.
- Nectero Medical — treatment for abdominal aortic aneurysm; board seat.
- Galvanize Therapeutics — pulsed electric field platform; board seat.
- Apreo Health — respiratory/pulmonary device company; board seat.
- iRhythm Technologies — ambulatory cardiac monitoring (Zio); reached IPO (Revelation-era).
- Omada Health — digital chronic-condition care (Revelation-era board seat).
- Respicardia — implantable therapy for central sleep apnea; acquired by Zoll Medical (Revelation-era).
- Evidation Health / Syapse — real-world-evidence and oncology data platforms (Revelation-era).
- Vertos Medical — minimally invasive spine devices; acquired by Stryker.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.